Published in Nat Med on August 26, 2007
Hepcidin and iron regulation, 10 years later. Blood (2011) 3.80
The serine protease TMPRSS6 is required to sense iron deficiency. Science (2008) 3.70
Regulation of cellular iron metabolism. Biochem J (2011) 3.03
Hepcidin and iron homeostasis. Biochim Biophys Acta (2012) 2.96
Afebrile Plasmodium falciparum parasitemia decreases absorption of fortification iron but does not affect systemic iron utilization: a double stable-isotope study in young Beninese women. Am J Clin Nutr (2010) 2.80
Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet (2014) 2.70
Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood (2009) 2.65
Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol (2010) 2.17
Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med (2010) 2.04
The role of hepcidin in iron metabolism. Acta Haematol (2009) 1.88
Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood (2008) 1.88
Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia. Blood (2015) 1.84
β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood (2011) 1.81
Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol (2010) 1.81
Hypoxic regulation of erythropoiesis and iron metabolism. Am J Physiol Renal Physiol (2010) 1.76
Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts. Blood (2011) 1.63
Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol (2012) 1.52
Mechanisms of mammalian iron homeostasis. Biochemistry (2012) 1.51
Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras/RAF and nutrient-dependent mTOR signaling. Blood (2014) 1.50
Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica (2009) 1.49
Increased serum hepcidin and alterations in blood iron parameters associated with asymptomatic P. falciparum and P. vivax malaria. Haematologica (2010) 1.47
Regulation of erythropoiesis by hypoxia-inducible factors. Blood Rev (2013) 1.47
Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice. J Clin Invest (2013) 1.44
Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood (2008) 1.43
Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis (2010) 1.43
Anemia: progress in molecular mechanisms and therapies. Nat Med (2015) 1.41
Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice. Blood (2010) 1.41
Attenuated inflammatory responses in hemochromatosis reveal a role for iron in the regulation of macrophage cytokine translation. J Immunol (2008) 1.40
Iron homeostasis and the inflammatory response. Annu Rev Nutr (2010) 1.40
Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest (2012) 1.35
Ineffective erythropoiesis and thalassemias. Curr Opin Hematol (2009) 1.34
The long history of iron in the Universe and in health and disease. Biochim Biophys Acta (2011) 1.33
Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica (2013) 1.32
Molecular basis of inherited microcytic anemia due to defects in iron acquisition or heme synthesis. Haematologica (2009) 1.32
The liver: conductor of systemic iron balance. Blood (2013) 1.30
A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease. BMC Med Genomics (2012) 1.29
Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci U S A (2009) 1.25
Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Blood (2012) 1.25
The treatment of secondary hemochromatosis. Dtsch Arztebl Int (2009) 1.24
Iron homeostasis: recently identified proteins provide insight into novel control mechanisms. J Biol Chem (2008) 1.22
Iron regulation by hepcidin. J Clin Invest (2013) 1.21
Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol (2010) 1.21
Iron Loading and Overloading due to Ineffective Erythropoiesis. Adv Hematol (2010) 1.19
Iron overload in sickle cell disease. Adv Hematol (2010) 1.15
Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia. Hematol Oncol Clin North Am (2010) 1.14
β-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med (2012) 1.14
Deficiency of liver sinusoidal scavenger receptors stabilin-1 and -2 in mice causes glomerulofibrotic nephropathy via impaired hepatic clearance of noxious blood factors. J Clin Invest (2011) 1.14
Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica (2011) 1.13
Missense SLC25A38 variations play an important role in autosomal recessive inherited sideroblastic anemia. Haematologica (2011) 1.11
Concise review: growth differentiation factor 15 in pathology: a clinical role? Stem Cells Transl Med (2013) 1.11
Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors. PLoS One (2009) 1.10
Genetic mechanisms and modifying factors in hereditary hemochromatosis. Nat Rev Gastroenterol Hepatol (2009) 1.10
Hepcidin modulation in human diseases: from research to clinic. World J Gastroenterol (2009) 1.09
Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One (2011) 1.08
The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica (2012) 1.08
The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev (2012) 1.07
Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol (2009) 1.06
β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica (2015) 1.06
Hepcidin in beta-thalassemia. Ann N Y Acad Sci (2010) 1.06
Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol (2014) 1.04
Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol (2013) 1.03
Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia. Haematologica (2015) 1.03
Iron deficiency in critically ill patients: highlighting the role of hepcidin. Crit Care (2011) 1.02
Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med (2012) 1.01
Severe iron deficiency blunts the response of the iron regulatory gene Hamp and pro-inflammatory cytokines to lipopolysaccharide. Haematologica (2010) 1.01
Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion (2010) 1.01
Ineffective erythropoiesis in β -thalassemia. ScientificWorldJournal (2013) 1.01
Ironing out the wrinkles in host defense: interactions between iron homeostasis and innate immunity. J Innate Immun (2009) 1.00
Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front Pharmacol (2014) 1.00
Erythropoiesis and iron sulfur cluster biogenesis. Adv Hematol (2010) 0.99
Hepcidin expression by human monocytes in response to adhesion and pro-inflammatory cytokines. Biochim Biophys Acta (2010) 0.99
Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica (2011) 0.99
The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program (2011) 0.99
Intestinal HIF2α promotes tissue-iron accumulation in disorders of iron overload with anemia. Proc Natl Acad Sci U S A (2013) 0.98
New insights into iron regulation and erythropoiesis. Curr Opin Hematol (2015) 0.98
beta-Thalassemia: HiJAKing Ineffective Erythropoiesis and Iron Overload. Adv Hematol (2010) 0.98
Crosstalk between Iron Metabolism and Erythropoiesis. Adv Hematol (2010) 0.98
Regulation of iron absorption in hemoglobinopathies. Curr Mol Med (2008) 0.97
Molecular liaisons between erythropoiesis and iron metabolism. Blood (2014) 0.97
Factors influencing disease phenotype and penetrance in HFE haemochromatosis. Hum Genet (2010) 0.97
The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. Blood (2013) 0.96
Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica (2013) 0.96
Iron and immunity: immunological consequences of iron deficiency and overload. Arch Immunol Ther Exp (Warsz) (2010) 0.95
Iron metabolism in thalassemia and sickle cell disease. Mediterr J Hematol Infect Dis (2009) 0.95
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion (2008) 0.94
Chuvash polycythemia VHLR200W mutation is associated with down-regulation of hepcidin expression. Blood (2011) 0.94
Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models. Ann N Y Acad Sci (2010) 0.93
The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant (2013) 0.93
Out of balance--systemic iron homeostasis in iron-related disorders. Nutrients (2013) 0.92
Iron metabolism: current facts and future directions. Biochem Med (Zagreb) (2012) 0.92
Pathophysiology and Clinical Manifestations of the β-Thalassemias. Cold Spring Harb Perspect Med (2012) 0.92
Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation. Haematologica (2010) 0.92
Superinfection in malaria: Plasmodium shows its iron will. EMBO Rep (2011) 0.91
Growth differentiation factor-15 (GDF-15) levels are associated with cardiac and renal injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. PLoS One (2014) 0.91
Known and potential roles of transferrin in iron biology. Biometals (2012) 0.91
Altered chromatin occupancy of master regulators underlies evolutionary divergence in the transcriptional landscape of erythroid differentiation. PLoS Genet (2014) 0.90
Hepcidin suppression and defective iron recycling account for dysregulation of iron homeostasis in heme oxygenase-1 deficiency. J Cell Mol Med (2009) 0.90
Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. J Blood Med (2011) 0.90
Future alternative therapies for β-thalassemia. Expert Rev Hematol (2009) 0.89
Effect of iron overload and iron deficiency on liver hemojuvelin protein. PLoS One (2012) 0.89
Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science (2004) 19.19
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest (2004) 11.05
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 9.01
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood (2002) 7.58
Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med (2012) 6.30
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet (2003) 5.82
NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc Natl Acad Sci U S A (2007) 5.14
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Regulation of iron metabolism by hepcidin. Annu Rev Nutr (2006) 3.96
Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood (2008) 3.71
Hepcidin is decreased in TFR2 hemochromatosis. Blood (2004) 3.46
Defensins of vertebrate animals. Curr Opin Immunol (2002) 3.41
Suppression of hepcidin during anemia requires erythropoietic activity. Blood (2006) 3.32
Paneth cell trypsin is the processing enzyme for human defensin-5. Nat Immunol (2002) 3.13
The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell (2007) 2.99
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? Nat Clin Pract Oncol (2006) 2.97
Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab (2010) 2.89
Hepcidin in iron overload disorders. Blood (2005) 2.88
SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell (2011) 2.73
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy (2009) 2.71
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther (2008) 2.69
Systemic iron homeostasis. Physiol Rev (2013) 2.69
Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood (2005) 2.66
Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood (2009) 2.65
Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2004) 2.65
Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.61
Interleukin-6 regulates the zinc transporter Zip14 in liver and contributes to the hypozincemia of the acute-phase response. Proc Natl Acad Sci U S A (2005) 2.60
Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica (2007) 2.52
Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood (2007) 2.51
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
On T2* magnetic resonance and cardiac iron. Circulation (2011) 2.33
Retracted The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab (2008) 2.25
Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol (2008) 2.25
RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. Nat Genet (2007) 2.22
Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology (2006) 2.21
Proinflammatory state, hepcidin, and anemia in older persons. Blood (2010) 2.19
Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation. J Invest Dermatol (2002) 2.17
The molecular basis of ferroportin-linked hemochromatosis. Proc Natl Acad Sci U S A (2005) 2.10
Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood (2005) 2.08
Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest (2006) 2.03
In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood (2010) 2.03
Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol (2007) 2.02
Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest (2003) 2.00
SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell (2013) 1.99
Human defensin gene copy number polymorphisms: comprehensive analysis of independent variation in alpha- and beta-defensin regions at 8p22-p23. Genomics (2005) 1.97
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood (2009) 1.96
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood (2009) 1.95
Detection, evaluation, and management of iron-restricted erythropoiesis. Blood (2010) 1.93
Hemoglobin H disease: not necessarily a benign disorder. Blood (2002) 1.91
The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem (2002) 1.89
The role of hepcidin in iron metabolism. Acta Haematol (2009) 1.88
Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol (2003) 1.88
Cathelicidins: a family of endogenous antimicrobial peptides. Curr Opin Hematol (2002) 1.86
SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J Biol Chem (2010) 1.86
Guidelines for assessing appropriateness of pediatric transfusion. Transfusion (2002) 1.84
Evidence for distinct pathways of hepcidin regulation by acute and chronic iron loading in mice. Hepatology (2011) 1.82
Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J Immunol (2003) 1.82
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med (2011) 1.79
Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood (2007) 1.78
Pediatric red blood cell transfusions increase resource use. J Pediatr (2003) 1.76
Posttranslational processing of hepcidin in human hepatocytes is mediated by the prohormone convertase furin. Blood Cells Mol Dis (2007) 1.76
A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia/hemoglobin E. Hum Genet (2010) 1.75
Blood transfusions in children: a multi-institutional analysis of practices and complications. Transfusion (2007) 1.74
End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood (2002) 1.73
Psychological stress downregulates epidermal antimicrobial peptide expression and increases severity of cutaneous infections in mice. J Clin Invest (2007) 1.72
Expression patterns of fetal hemoglobin in sickle cell erythrocytes are both patient- and treatment-specific during childhood. Pediatr Blood Cancer (2011) 1.69
Antimicrobial components of vaginal fluid. Am J Obstet Gynecol (2002) 1.67
Severe hemochromatosis in a Portuguese family associated with a new mutation in the 5'-UTR of the HAMP gene. Blood (2004) 1.64
Antimicrobial activity of innate immune molecules against Streptococcus pneumoniae, Moraxella catarrhalis and nontypeable Haemophilus influenzae. BMC Infect Dis (2004) 1.63
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res (2006) 1.61
T-type calcium channel blockade improves survival and cardiovascular function in thalassemic mice. Eur J Haematol (2012) 1.61
The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation. Blood (2003) 1.60
The N-terminus of hepcidin is essential for its interaction with ferroportin: structure-function study. Blood (2005) 1.60
Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.59
Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components. Transfusion (2011) 1.59
Urinary hepcidin in congenital chronic anemias. Pediatr Blood Cancer (2007) 1.58
Cationic polypeptides are required for antibacterial activity of human airway fluid. J Immunol (2002) 1.58
Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol (2005) 1.58
Targeted modification of a human beta-globin locus BAC clone using GET Recombination and an I-Scei counterselection cassette. Genomics (2003) 1.58
Increased genomic copy number of DEFA1/DEFA3 is associated with susceptibility to severe sepsis in Chinese Han population. Anesthesiology (2010) 1.58
Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res (2008) 1.57
A transcriptional signaling pathway in the IFN system mediated by 2'-5'-oligoadenylate activation of RNase L. Proc Natl Acad Sci U S A (2005) 1.56
Transfusion management strategies: a survey of practicing pediatric hematology/oncology specialists. Pediatr Blood Cancer (2005) 1.56
Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J Immunol (2006) 1.55
By IL-1 signaling, monocyte-derived cells dramatically enhance the epidermal antimicrobial response to lipopolysaccharide. J Immunol (2003) 1.54
Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.54
Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet (2003) 1.54
Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome. Transfusion (2013) 1.53
Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion (2010) 1.51
The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood (2009) 1.51
Transfusion-associated hyperkalemic cardiac arrest in pediatric patients receiving massive transfusion. Transfusion (2013) 1.51
Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood (2012) 1.51